
what's coming up
Please fill in this form if you're interested in joining as a student affiliate.
Stay updated on our latest events and news by joining our mailing list.
Interested in sharing your expertise? Apply to give a talk at our next seminar.
Speaker: Ayush Noori
Time: 17:30-18:30
Levett Room, Wolfson College & Online (Teams link).
Biography:
Ayush Noori is a Rhodes Scholar, Encode: AI for Science PhD Fellow, and D.Phil. student in Engineering Science in the Computational Health Informatics Lab at the University of Oxford. Driven by personal experiences, Ayush conducts research at the interface of artificial intelligence (AI), translational neuroscience, and precision medicine. He seeks to develop AI technologies that expand the frontier of personalized diagnosis and treatment for neurological disorders and other challenging medical conditions. His research efforts across Harvard Medical School, the Wyss Institute, and Massachusetts General Hospital have produced over 30 papers (including nine first or co-first author works) published in Cell, Nature Neuroscience, Nature Machine Intelligence, Nature Aging, npj Digital Medicine, Alzheimer’s & Dementia, and other peer-reviewed journals. Ayush received a Bachelor’s in Computer Science and Neuroscience and a concurrent Master’s in Computer Science from Harvard University.
Abstract:
Neurological diseases are the leading global cause of disability, yet most lack disease-modifying treatments. We developed CIPHER, a graph AI model that generates mechanistic hypotheses for neurological disease. CIPHER uses a heterogeneous graph transformer contextualized to the adult human brain. CIPHER generated predictions across Parkinson’s disease (PD), bipolar disorder (BD), and Alzheimer’s disease (AD), which we validated using three independent biological systems. In PD, CIPHER linked genetic risk loci to genes essential for dopaminergic neuron survival and identified pesticides toxic to patient-derived neurons, including the insecticide Naled ranked within the top 6.75% of predictions. In silico CIPHER screens reproduced six genome-wide α-synuclein experiments, including a split-ubiquitin yeast two-hybrid system (normalized enrichment score [NES] = 2.27, FDR-adjusted p < 1E-4), an ascorbate peroxidase proximity labeling assay (NES = 2.22, FDR < 1E-4), and a high-depth targeted exome screen in 496 synucleinopathy patients (NES = 1.73, FDR < 1.9E-3). In BD, CIPHER nominated calcitriol as a candidate drug that reversed proteomic alterations in cortical organoids derived from BD patients. In AD, we conducted emulated clinical trials on cohorts involving n = 610,524 patients at Mass General Brigham, confirming that five CIPHER-predicted drugs were associated with reduced seven-year dementia risk (minimum hazard ratio = 0.63, 95% CI: 0.53–0.75, p < 1E-7). CIPHER generated and validated mechanistic hypotheses across molecular, organoid, and clinical systems, defining a path for AI-driven discovery in neurological disease.
Speaker: Tim Reichelt
Time: 17:30-18:30
Levett Room, Wolfson College & Online (Teams link).
Biography:
I am an Encode AI Fellow in the Climate Processes group led by Prof Philip Stier. As part of the Encode fellowship, we are building a generative model for cloud structures with the primary goal is to constrain cloud climate feedbacks. Before starting the fellowship, I was conducting research on compression algorithms for climate and weather data funded by the Embed2Scale project.
I completed my PhD as part of the EPSRC Centre for Doctoral Training in Autonomous Intelligent Machines and Systems here in Oxford. In my research I developed novel Bayesian inference algorithms for models defined through probabilistic programs.
Abstract:
We are building a generative model for cloud structures conditioned on environmental conditions, integrating both high-resolution satellite data and reanalysis data. By being able to generate and reconstruct cloud structures under varying environmental conditions, the model will allow us to reduce uncertainties in future climate predictions and facilitate the detection and quantification of cloud feedbacks across the satellite record. This purely data-driven approach to constraining cloud feedbacks will be complementary to existing work that relies on physics-based models.
Speaker: Konstantin Hemker
Time: 17:30-18:30
Levett Room, Wolfson College & Online (Teams link).
Biography:
I grew up in the beautiful city of Hamburg in Germany and moved to the UK after high school for my undergraduate degree at the London School of Economics. About a year into my time at LSE, I realised that I was more interested in mathematics & statistics than the economics aspects of my degree, which eventually led me to self-educate myself in Computer Science on the side. I then did a Master's in Computer Science at Imperial College London, where I focussed on various disciplines ranging from Cybersecurity to Natural Language Processing. I really enjoyed Natural Language Processing and Machine Learning more generally and started working as a Senior Data Scientist for the Boston Consulting Group for a few years. At BCG, I primarily worked on drug yield optimisation of Pharmaceutical API production as well as various other interesting modelling challenges in the pharmaceutical industry, travel & tourism industry, the public sector, and even the dating app market. Working alongside chemical engineers on pharma production sites originally piqued my interest in bioinformatics and my current research is an evolution of this (after many, many iterations).
Abstract:
We are building an automated platform that uses artificial intelligence to design and optimize nanoparticles for medical applications such as enabling brain-specific delivery. Our system combines robotic laboratory equipment with AI algorithms that learn from experimental results to rapidly discover optimal nanoparticle recipes, replacing the current time-consuming trial-and-error approach. The platform will process hundreds of different nanoparticle formulations simultaneously, using real-time measurements of particle properties to guide the AI in selecting the most promising combinations. By automating and accelerating nanoparticle development, we aim to reduce optimization time from months to days while creating better-performing particles for medical applications such as neurological diseases, potentially accelerating the development of new treatments and therapies.
Events held and scheduled by us
Watch recordings of past events on our YouTube channel.


























































































